A5103039502- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Advanced Breast Cancer Therapies
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Glioma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- PARP inhibition in cancer therapy
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- Adrenal and Paraganglionic Tumors
- Cancer Diagnosis and Treatment
- Helicobacter pylori-related gastroenterology studies
- Endometrial and Cervical Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
Kanagawa Cardiovascular and Respiratory Center
2013-2023
Taipei Veterans General Hospital
2013-2023
National Cheng Kung University Hospital
2013-2023
National Taiwan University Hospital
2013-2023
Angiologica (Italy)
2013-2023
Ministry of Health of the Russian Federation
2017-2020
Russian Cancer Research Center NN Blokhin
2011-2020
National Medical Research Center of Cardiology
2019-2020
Ministry of Health
2017
Russian Academy of Sciences
2005-2016
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human 2 (HER2/ErbB2), and ErbB4 has wide-spectrum preclinical activity against EGFR mutations. A phase II afatinib in mutation-positive lung adenocarcinoma demonstrated high response rates progression-free survival (PFS).
Purpose Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage. Methods This study was conducted in 24 countries 146 centers. One thousand fifty-three patients were stratified (center, number of metastatic sites, prior adjuvant therapy, measurable cancer) randomly assigned. received either S-1 at 50 mg/m 2 divided two daily doses for 21 days...
Maintenance therapy is associated with improved survival in patients non-small-cell lung cancer (NSCLC), but few studies have compared active agents this setting. AVAPERL evaluated the safety and efficacy of bevacizumab or without pemetrexed as continuation maintenance treatment.Patients advanced nonsquamous NSCLC received first-line 7.5 mg/kg, cisplatin 75 mg/m(2), 500 mg/m(2) once every 3 weeks for four cycles. Those achieving response stable disease were randomly assigned at a ratio 1:1...
To compare the efficacy of aflibercept (ziv-aflibercept), a recombinant human fusion protein targeting vascular endothelial growth factor (VEGF) pathway, with or without docetaxel in platinum-pretreated patients advanced metastatic nonsquamous non-small-cell lung cancer.In this international, double-blind, placebo-controlled phase III trial, 913 were randomly assigned to (ziv-)aflibercept 6 mg/kg intravenous (IV; n = 456) IV placebo (n 457), both administered every 3 weeks and combination 75...
LBA7500 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Monday edition ASCO Daily News.
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human 2 (HER2/ErbB2), and ErbB4 has wide-spectrum preclinical activity against
LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the efficacy safety A compared with pemetrexed/cisplatin (PC) in pts mutation positive advanced lung adenocarcinoma. Methods: Following central testing for mutations (companion diagnostic TheraScreen RGQ PCR kit), 345 (stage IIIB/IV, PS 0–1, chemo-naive) were randomized 2:1 (A: 230; PC: 115) to daily 40 mg or iv PC...
Purpose: PARP plays an important role in DNA repair. Veliparib, a inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin paclitaxel. The primary endpoint this phase II trial determined whether addition veliparib to paclitaxel improved progression-free survival (PFS) previously untreated patients advanced/metastatic non-small cell lung cancer.Experimental Design: Patients were randomized 2:1 either or placebo. Veliparib (120 mg) placebo was given...
Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived (PDGF) receptors, has single-agent activity in non-small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin paclitaxel as first-line therapy advanced nonsquamous NSCLC.